CTI BioPharma Corp (fka CTIC)

[medimpact]

This is what's supposed to be happening on the 9th:
"Cell TherapeuticsInc. (CTIC) recently announced that the resubmitted new drug application (“NDA”) for its lead pipeline candidate pixantrone will be reviewed by a panel of the US Food & Drug Administration (“FDA”) on February, 9, 2012".
The panel has to review the resubmitted application and make a recommendation for the April FDA meeting. If they make a positive one + the European approval + April final approval, I think my estimate of a pps close to $20 is not too far fetched. Then again, this might all be wishful thinking.